AARTI PHARMALABS LIMITED Intrinsic Value

AARTIPHARM · Healthcare · Current price ₹866.1

Full stock page
DocStoX fair value
₹437
low confidence
Current price
₹866
Upside to fair value
-49.5%
Verdict
Avoid
Quality score
2.6 / 10
Model it yourself — Intrinsic Value Calculator
Opens pre-filled with AARTI PHARMALABS LIMITED's latest numbers.

Is AARTI PHARMALABS LIMITED undervalued?

DocStoX estimates the fair value of AARTI PHARMALABS LIMITED at ₹437 per share, versus the current market price of ₹866. That puts the stock about -49.5% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.

How this fair value is calculated

This estimate blends 4 independent methods: Residual income (₹222), Relative P/E (₹697), Graham floor (₹319), Analyst target (₹740). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.

Bear, base and bull scenarios

Our scenarios span ₹222 (bear) to ₹437 (base) to ₹740 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.

Margin of safety

Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹866 versus an intrinsic value of ₹437, AARTI PHARMALABS LIMITED currently offers -49.5% of negative margin (i.e. a premium).

More on AARTI PHARMALABS LIMITED

Fair ValueDCFValuationFinancial RatiosPeers

DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.